Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Klotho is required for metabolic activity of fibroblast growth factor 21
Yasushi Ogawa*,
Hiroshi Kurosu*,
Masaya Yamamoto*,
Animesh Nandi*,
Kevin P. Rosenblatt*,
Regina Goetz,
Anna V. Eliseenkova,
Moosa Mohammadi, and
Makoto Kuro-o*,
*Department of Pathology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390; and Department of Pharmacology, New York University School of Medicine, 550 First Avenue, MSB 425, New York, NY 10016
Edited by Michael S. Brown, University of Texas Southwestern Medical Center, Dallas, TX, and approved March 26, 2007
Received for publication February 21, 2007.
Abstract:
Fibroblast growth factor 21 (FGF21) is a liver-derived endocrinefactor that stimulates glucose uptake in adipocytes. Here, weshow that FGF21 activity depends on Klotho, a single-pass transmembraneprotein whose expression is induced during differentiation frompreadipocytes to adipocytes. Klotho physically interacts withFGF receptors 1c and 4, thereby increasing the ability of theseFGF receptors to bind FGF21 and activate the MAP kinase cascade.Knockdown of Klotho expression by siRNA in adipocytes diminishesglucose uptake induced by FGF21. Importantly, administrationof FGF21 into mice induces MAP kinase phosphorylation in whiteadipose tissue and not in tissues without Klotho expression.Thus, Klotho functions as a cofactor essential for FGF21 activity.
Freely available online through the PNAS open access option.
Author contributions: Y.O. and H.K. contributed equally to thiswork; Y.O., H.K., and M.K. designed research; Y.O, H.K., M.Y.,A.N., and M.K. performed research; A.N., K.P.R., R.G., A.V.E.,and M.M. contributed new reagents/analytic tools; Y.O., H.K.,and M.K. analyzed data; and Y.O., H.K., M.M. and M.K. wrotethe paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
To whom correspondence should be addressed. E-mail: makoto.kuro-o{at}utsouthwestern.edu
The editors suggest the following Related Resources on Science sites:
In Science Signaling
EDITORS' CHOICE
L. Bryan Ray (17 April 2007) Sci. STKE2007 (382), tw133.
[DOI: 10.1126/stke.3822007tw133] |Abstract »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Dual actions of fibroblast growth factor 19 on lipid metabolism.
X. Wu, H. Ge, H. Baribault, J. Gupte, J. Weiszmann, B. Lemon, J. Gardner, P. Fordstrom, J. Tang, M. Zhou, et al. (2013)
J. Lipid Res.
54, 325-332
|Abstract »|Full Text »|PDF »
Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans.
S. Kralisch, A. Tonjes, K. Krause, J. Richter, U. Lossner, P. Kovacs, T. Ebert, M. Bluher, M. Stumvoll, and M. Fasshauer (2013)
J. Endocrinol.
216, 135-143
|Abstract »|Full Text »|PDF »
Fibroblast Growth Factor 21 Predicts the Metabolic Syndrome and Type 2 Diabetes in Caucasians.
T. Bobbert, F. Schwarz, A. Fischer-Rosinsky, A. F. H. Pfeiffer, M. Mohlig, K. Mai, and J. Spranger (2013)
Diabetes Care
36, 145-149
|Abstract »|Full Text »|PDF »
Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the {beta}Klotho/FGFR1c Receptor Complex.
I. N. Foltz, S. Hu, C. King, X. Wu, C. Yang, W. Wang, J. Weiszmann, J. Stevens, J. S. Chen, N. Nuanmanee, et al. (2012)
Science Translational Medicine
4, 162ra153
|Abstract »|Full Text »|PDF »
Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor {beta}-Klotho.
T. Fu, S.-E. Choi, D.-H. Kim, S. Seok, K. M. Suino-Powell, H. E. Xu, and J. K. Kemper (2012)
PNAS
109, 16137-16142
|Abstract »|Full Text »|PDF »
MECHANISMS IN ENDOCRINOLOGY: Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21.
P. Iglesias, R. Selgas, S. Romero, and J. J. Diez (2012)
Eur. J. Endocrinol.
167, 301-309
|Abstract »|Full Text »|PDF »
TNF-{alpha} Represses {beta}-Klotho Expression and Impairs FGF21 Action in Adipose Cells: Involvement of JNK1 in the FGF21 Pathway.
J. Diaz-Delfin, E. Hondares, R. Iglesias, M. Giralt, C. Caelles, and F. Villarroya (2012)
Endocrinology
153, 4238-4245
|Abstract »|Full Text »|PDF »
Searching for ways to switch on brown fat: are we getting warmer?.
Conversion of a Paracrine Fibroblast Growth Factor into an Endocrine Fibroblast Growth Factor.
R. Goetz, M. Ohnishi, S. Kir, H. Kurosu, L. Wang, J. Pastor, J. Ma, W. Gai, M. Kuro-o, M. S. Razzaque, et al. (2012)
J. Biol. Chem.
287, 29134-29146
|Abstract »|Full Text »|PDF »
Fibroblast Growth Factor 21 (FGF21) Inhibits Chondrocyte Function and Growth Hormone Action Directly at the Growth Plate.
S. Wu, A. Levenson, A. Kharitonenkov, and F. De Luca (2012)
J. Biol. Chem.
287, 26060-26067
|Abstract »|Full Text »|PDF »
Dynamics and Distribution of Klotho{beta} (KLB) and Fibroblast Growth Factor Receptor-1 (FGFR1) in Living Cells Reveal the Fibroblast Growth Factor-21 (FGF21)-induced Receptor Complex.
A. Y. K. Ming, E. Yoo, E. N. Vorontsov, S. M. Altamentova, D. M. Kilkenny, and J. V. Rocheleau (2012)
J. Biol. Chem.
287, 19997-20006
|Abstract »|Full Text »|PDF »
R. Goetz, M. Ohnishi, X. Ding, H. Kurosu, L. Wang, J. Akiyoshi, J. Ma, W. Gai, Y. Sidis, N. Pitteloud, et al. (2012)
Mol. Cell. Biol.
32, 1944-1954
|Abstract »|Full Text »|PDF »
Relationship of Serum Fibroblast Growth Factor 21 with Abnormal Glucose Metabolism and Insulin Resistance: The Baltimore Longitudinal Study of Aging.
R. D. Semba, K. Sun, J. M. Egan, C. Crasto, O. D. Carlson, and L. Ferrucci (2012)
J. Clin. Endocrinol. Metab.
97, 1375-1382
|Abstract »|Full Text »|PDF »
Endocrine fibroblast growth factors 15/19 and 21: from feast to famine.
M. J. Potthoff, S. A. Kliewer, and D. J. Mangelsdorf (2012)
Genes & Dev.
26, 312-324
|Abstract »|Full Text »|PDF »
Regulation and Function of the FGF23/Klotho Endocrine Pathways.
Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance.
C. Hale, M. M. Chen, S. Stanislaus, N. Chinookoswong, T. Hager, M. Wang, M. M. Veniant, and J. Xu (2012)
Endocrinology
153, 69-80
|Abstract »|Full Text »|PDF »
Amelioration of Type 2 Diabetes by Antibody-Mediated Activation of Fibroblast Growth Factor Receptor 1.
A.-L. Wu, G. Kolumam, S. Stawicki, Y. Chen, J. Li, J. Zavala-Solorio, K. Phamluong, B. Feng, L. Li, S. Marsters, et al. (2011)
Science Translational Medicine
3, 113ra126
|Abstract »|Full Text »|PDF »
Plasma FGF21 Is Elevated by the Intense Lipid Mobilization of Lactation.
K. M. Schoenberg, S. L. Giesy, K. J. Harvatine, M. R. Waldron, C. Cheng, A. Kharitonenkov, and Y. R. Boisclair (2011)
Endocrinology
152, 4652-4661
|Abstract »|Full Text »|PDF »
Fibroblast Growth Factor 21 Induces Glucose Transporter-1 Expression through Activation of the Serum Response Factor/Ets-Like Protein-1 in Adipocytes.
X. Ge, C. Chen, X. Hui, Y. Wang, K. S. L. Lam, and A. Xu (2011)
J. Biol. Chem.
286, 34533-34541
|Abstract »|Full Text »|PDF »
Nrf2 Represses FGF21 During Long-Term High-Fat Diet-Induced Obesity in Mice.
D. V. Chartoumpekis, P. G. Ziros, A. I. Psyrogiannis, A. G. Papavassiliou, V. E. Kyriazopoulou, G. P. Sykiotis, and I. G. Habeos (2011)
Diabetes
60, 2465-2473
|Abstract »|Full Text »|PDF »
Integrated Regulation of Hepatic Metabolism by Fibroblast Growth Factor 21 (FGF21) in Vivo.
f. M. Fisher, J. L. Estall, A. C. Adams, P. J. Antonellis, H. A. Bina, J. S. Flier, A. Kharitonenkov, B. M. Spiegelman, and E. Maratos-Flier (2011)
Endocrinology
152, 2996-3004
|Abstract »|Full Text »|PDF »
Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis.
E. M. Domouzoglou and E. Maratos-Flier (2011)
Am J Clin Nutr
93, 901S-905S
|Abstract »|Full Text »|PDF »
The Cooperation of FGF Receptor and Klotho Is Involved in Excretory Canal Development and Regulation of Metabolic Homeostasis in Caenorhabditis elegans.
U. M. Polanska, E. Edwards, D. G. Fernig, and T. K. Kinnunen (2011)
J. Biol. Chem.
286, 5657-5666
|Abstract »|Full Text »|PDF »
Circulating Fibroblast Growth Factor-23 Is Associated With Fat Mass and Dyslipidemia in Two Independent Cohorts of Elderly Individuals.
M. A. I. Mirza, J. Alsio, A. Hammarstedt, R. G. Erben, K. Michaelsson, A. Tivesten, R. Marsell, E. Orwoll, M. K. Karlsson, O. Ljunggren, et al. (2011)
Arterioscler Thromb Vasc Biol
31, 219-227
|Abstract »|Full Text »|PDF »
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State.
f. M. Fisher, P. C. Chui, P. J. Antonellis, H. A. Bina, A. Kharitonenkov, J. S. Flier, and E. Maratos-Flier (2010)
Diabetes
59, 2781-2789
|Abstract »|Full Text »|PDF »
Research Resource: Comprehensive Expression Atlas of the Fibroblast Growth Factor System in Adult Mouse.
K. Fon Tacer, A. L. Bookout, X. Ding, H. Kurosu, G. B. John, L. Wang, R. Goetz, M. Mohammadi, M. Kuro-o, D. J. Mangelsdorf, et al. (2010)
Mol. Endocrinol.
24, 2050-2064
|Abstract »|Full Text »|PDF »
Metabolic Regulator {beta}Klotho Interacts with Fibroblast Growth Factor Receptor 4 (FGFR4) to Induce Apoptosis and Inhibit Tumor Cell Proliferation.
Y. Luo, C. Yang, W. Lu, R. Xie, C. Jin, P. Huang, F. Wang, and W. L. McKeehan (2010)
J. Biol. Chem.
285, 30069-30078
|Abstract »|Full Text »|PDF »
Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1{alpha} pathway.
M. D. L. Chau, J. Gao, Q. Yang, Z. Wu, and J. Gromada (2010)
PNAS
107, 12553-12558
|Abstract »|Full Text »|PDF »
Fibroblast Growth Factor 21 Action in the Brain Increases Energy Expenditure and Insulin Sensitivity in Obese Rats.
D. A. Sarruf, J. P. Thaler, G. J. Morton, J. German, J. D. Fischer, K. Ogimoto, and M. W. Schwartz (2010)
Diabetes
59, 1817-1824
|Abstract »|Full Text »|PDF »
FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation.
X. Wu, H. Ge, B. Lemon, S. Vonderfecht, J. Weiszmann, R. Hecht, J. Gupte, T. Hager, Z. Wang, R. Lindberg, et al. (2010)
J. Biol. Chem.
285, 5165-5170
|Abstract »|Full Text »|PDF »
Relevant use of Klotho in FGF19 subfamily signaling system in vivo.
K.-i. Tomiyama, R. Maeda, I. Urakawa, Y. Yamazaki, T. Tanaka, S. Ito, Y. Nabeshima, T. Tomita, S. Odori, K. Hosoda, et al. (2010)
PNAS
107, 1666-1671
|Abstract »|Full Text »|PDF »
Fibroblast growth factor 21: from pharmacology to physiology.
Fibroblast Growth Factor 21-Deficient Mice Demonstrate Impaired Adaptation to Ketosis.
M. K. Badman, A. Koester, J. S. Flier, A. Kharitonenkov, and E. Maratos-Flier (2009)
Endocrinology
150, 4931-4940
|Abstract »|Full Text »|PDF »
Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
J. Xu, S. Stanislaus, N. Chinookoswong, Y. Y. Lau, T. Hager, J. Patel, H. Ge, J. Weiszmann, S.-C. Lu, M. Graham, et al. (2009)
Am J Physiol Endocrinol Metab
297, E1105-E1114
|Abstract »|Full Text »|PDF »
Circulating Fibroblast Growth Factor 21 Is Induced by Peroxisome Proliferator-Activated Receptor Agonists But Not Ketosis in Man.
C. Christodoulides, P. Dyson, D. Sprecher, K. Tsintzas, and F. Karpe (2009)
J. Clin. Endocrinol. Metab.
94, 3594-3601
|Abstract »|Full Text »|PDF »
Fibroblast Growth Factor 21 Controls Glycemia via Regulation of Hepatic Glucose Flux and Insulin Sensitivity.
E. D. Berglund, C. Y. Li, H. A. Bina, S. E. Lynes, M. D. Michael, A. B. Shanafelt, A. Kharitonenkov, and D. H. Wasserman (2009)
Endocrinology
150, 4084-4093
|Abstract »|Full Text »|PDF »
Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
X. Wu, H. Ge, B. Lemon, J. Weiszmann, J. Gupte, N. Hawkins, X. Li, J. Tang, R. Lindberg, and Y. Li (2009)
PNAS
106, 14379-14384
|Abstract »|Full Text »|PDF »
FGF21 induces PGC-1{alpha} and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response.
M. J. Potthoff, T. Inagaki, S. Satapati, X. Ding, T. He, R. Goetz, M. Mohammadi, B. N. Finck, D. J. Mangelsdorf, S. A. Kliewer, et al. (2009)
PNAS
106, 10853-10858
|Abstract »|Full Text »|PDF »
FGF15/FGFR4 Integrates Growth Factor Signaling with Hepatic Bile Acid Metabolism and Insulin Action.
Essential role of glucose transporter GLUT3 for post-implantation embryonic development.
S Schmidt, A Hommel, V Gawlik, R Augustin, N Junicke, S Florian, M Richter, D J Walther, D Montag, H-G Joost, et al. (2009)
J. Endocrinol.
200, 23-33
|Abstract »|Full Text »|PDF »
Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice.
J. Xu, D. J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits, S. Vonderfecht, R. Hecht, Y.-S. Li, R. A. Lindberg, et al. (2009)
Diabetes
58, 250-259
|Abstract »|Full Text »|PDF »
Fibroblast Growth Factor 21 Corrects Obesity in Mice.
T. Coskun, H. A. Bina, M. A. Schneider, J. D. Dunbar, C. C. Hu, Y. Chen, D. E. Moller, and A. Kharitonenkov (2008)
Endocrinology
149, 6018-6027
|Abstract »|Full Text »|PDF »
C-terminal Tail of FGF19 Determines Its Specificity toward Klotho Co-receptors.
X. Wu, B. Lemon, X. Li, J. Gupte, J. Weiszmann, J. Stevens, N. Hawkins, W. Shen, R. Lindberg, J.-L. Chen, et al. (2008)
J. Biol. Chem.
283, 33304-33309
|Abstract »|Full Text »|PDF »
Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans.
X. Zhang, D. C.Y. Yeung, M. Karpisek, D. Stejskal, Z.-G. Zhou, F. Liu, R. L.C. Wong, W.-S. Chow, A. W.K. Tso, K. S.L. Lam, et al. (2008)
Diabetes
57, 1246-1253
|Abstract »|Full Text »|PDF »
{beta}Klotho Is Required for Fibroblast Growth Factor (FGF) 21 Signaling through FGF Receptor (FGFR) 1c and FGFR3c.
M. Suzuki, Y. Uehara, K. Motomura-Matsuzaka, J. Oki, Y. Koyama, M. Kimura, M. Asada, A. Komi-Kuramochi, S. Oka, and T. Imamura (2008)
Mol. Endocrinol.
22, 1006-1014
|Abstract »|Full Text »|PDF »
Identification of a Domain within Peroxisome Proliferator-Activated Receptor {gamma} Regulating Expression of a Group of Genes Containing Fibroblast Growth Factor 21 That Are Selectively Repressed by SIRT1 in Adipocytes.
Co-receptor Requirements for Fibroblast Growth Factor-19 Signaling.
X. Wu, H. Ge, J. Gupte, J. Weiszmann, G. Shimamoto, J. Stevens, N. Hawkins, B. Lemon, W. Shen, J. Xu, et al. (2007)
J. Biol. Chem.
282, 29069-29072
|Abstract »|Full Text »|PDF »
Liver-specific Activities of FGF19 Require Klotho beta.
B. C. Lin, M. Wang, C. Blackmore, and L. R. Desnoyers (2007)
J. Biol. Chem.
282, 27277-27284
|Abstract »|Full Text »|PDF »
Tissue-specific Expression of betaKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21.
H. Kurosu, M. Choi, Y. Ogawa, A. S. Dickson, R. Goetz, A. V. Eliseenkova, M. Mohammadi, K. P. Rosenblatt, S. A. Kliewer, and M. Kuro-o (2007)
J. Biol. Chem.
282, 26687-26695
|Abstract »|Full Text »|PDF »